2024
AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial
Shimony S, Murdock H, Keating J, Reilly C, Tsai H, Gibson C, Faderl S, Wagner T, Dronamraju N, Lin T, Ritchie E, Prebet T, Cortes J, Uy G, Lancet J, Neuberg D, Stone R, Lindsley R. AML-MR Mutations Drive the Benefit of CPX-351 over 7+3 in the Pivotal Phase 3 AML Trial. Blood 2024, 144: 60-60. DOI: 10.1182/blood-2024-200413.Peer-Reviewed Original ResearchAcute myeloid leukemiaTherapy-related AMLGermline DDX41 mutationsCPX-351Platelet recovery timeTP53 mutationsOverall survivalDDX41 mutationsTreatment armsCR/CRi rateMedian OSS-AMLPrognosis of t-AMLTherapy-related acute myeloid leukemiaAnalyzed outcomesSecondary acute myeloid leukemiaAML classificationSubsets of acute myeloid leukemiaConcurrent TP53 mutationImproved overall survivalHistory of MDSDe novoPhase 3 trialFavorable treatment outcomesTargeted mutation analysisFuture directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology
Della Porta M, Bewersdorf J, Wang Y, Hasserjian R. Future directions in myelodysplastic syndromes/neoplasms and acute myeloid leukaemia classification: from blast counts to biology. Histopathology 2024, 86: 158-170. PMID: 39450427, DOI: 10.1111/his.15353.Peer-Reviewed Original ResearchAcute myeloid leukemiaIntegration of genomic dataGenomic informationGenomic dataPresence of SF3B1 mutationsDisease entityMethylation profilesAML classificationRecurrent genetic abnormalitiesHaematopoietic cell proliferationPercentage of myeloblastsGene expressionGenetic featuresMultiple diagnostic modalitiesPatient risk stratificationSF3B1 mutationsBlast countDisease pathogenesisGenetic abnormalitiesCell proliferationTP53 abnormalitiesDiagnostic modalitiesMyeloid leukemiaBone marrowPatient cohort
2023
Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems?
Carlson K, Cunningham A, Stahl M, Winer E, Michaelis L. Diagnostic Precision or Pitfalls: How to Apply the New Acute Myeloid Leukemia Classification Systems? Acta Haematologica 2023, 147: 122-133. PMID: 38071966, DOI: 10.1159/000535607.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaAML classificationWorld Health OrganizationMyelodysplasia-related acute myeloid leukemiaClassification of acute myeloid leukemiaRevised 4th editionWorld Health Organization blue bookTreatment decision-makingMyeloid leukemiaClassification systemTherapy-relatedClinical trialsBlast thresholdHematologic oncologistsClinical scenariosTreatment decisionsDiagnostic precisionHealth Organization
2015
Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia
Ziai JM, Siddon AJ. Pathology Consultation on Gene Mutations in Acute Myeloid Leukemia. American Journal Of Clinical Pathology 2015, 144: 539-554. PMID: 26386075, DOI: 10.1309/ajcp77zfpuqgygwy.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaMyeloid leukemiaGene mutationsTypes of AMLNormal acute myeloid leukemiaAggressive chemotherapy regimensMinimal residual diseaseChemotherapy regimensDisease courseImmunophenotypic featuresResidual diseaseTherapeutic regimensPatient prognosisPrognostic informationTherapeutic implicationsAML classificationIndividualized approachPathology consultationFatal diseasePrognosisHeterogeneous groupRelevant gene mutationsDiseaseLaboratory evaluationRegimens
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply